Targets › CA4
3 programs from 3 companies in 26 trials: 10 Phase 4, 8 Phase 1, 7 Phase 2, 1 Phase 3; Neurology, Metabolic and endocrine, Psychiatry; next expected readout Dec 2026.
Catalyzes the reversible hydration of carbon dioxide into bicarbonate and protons and thus is essential to maintaining intracellular and extracellular pH. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid. (UniProt, P22748)
Open in Phaseline: the race on CA4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Colorado, Denver | Methazolamide Carbonic anhydrase VII inhibitor; Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor | CA7, CA1, CA2, CA4 | Phase 4 | Glaucoma, Open-Angle | – |
| Upsher-Smith Laboratories | Topiramate Carbonic anhydrase II inhibitor; Carbonic anhydrase IV inhibitor; Glutamate receptor ionotropic AMPA antagonist | CA2, CA4, GRIA4, GRIA3, GRIA2 | Phase 4 | Migraine Disorders; Obesity; Ménière; Liver Cirrhoses … | – |
| Shionogi | Acetazolamide Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor; Carbonic anhydrase XII inhibitor | CA1, CA2, CA12, CA4 | Phase 2 | Sleep Apnea; Hypobaric Hypoxia; High Altitude Effects; Post Operative Pain … | Dec 2026 |
Sleep Apnea (3) Obstructive Sleep Apnea (3) Glaucoma, Open-Angle (1) Migraine Disorders (1) Obesity (1) Ménière (1) Liver Cirrhoses (1) Post Traumatic Stress Disorder (1) Hypobaric Hypoxia (1) High Altitude Effects (1) Post Operative Pain (1) Sleep Disordered Breathing (1)
small molecule (3)
University of Colorado, Denver (1) Upsher-Smith Laboratories (1) Shionogi (1)
CA2 (3) CA1 (2) CA7 (1) GRIA4 (1) GRIA3 (1) GRIA2 (1) CA12 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.